PCMA warns against cuts to Medicare in 21st Century Cures draft | Press release: PCMA Statement on 21st Century Cures | Should the ACA penalties be adjusted?
May 22, 2015
PCMA SmartBrief
News for the PBM Industry

Featured Story
PCMA warns against cuts to Medicare in 21st Century Cures draft
A draft of the 21st Century Cures Act that was unanimously endorsed Thursday by the House Energy and Commerce Committee includes language that could cut billions from Medicare, PCMA said in a statement. "We urge policymakers to explore different offsets that don't pose new risks to other parts of the health care delivery system," PCMA said. Bloomberg Government (subscription required) (5/21)
Share: LinkedInTwitterFacebookGoogle+Email
Legislative & Regulatory News
Should the ACA penalties be adjusted?
Relatively few uninsured taxpayers took advantage of a special enrollment window to avoid paying a tax penalty, suggesting that the penalty might be too low to prompt enrollment, some industry observers say. The New York Times (tiered subscription model) (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
Health insurers in some states want to hike premiums
Health insurance providers are seeking significant increases in premiums in several states in a move they say is necessary to cover the medical costs of individuals who have newly enrolled as part of the Affordable Care Act. The Wall Street Journal (tiered subscription model) (5/21)
Share: LinkedInTwitterFacebookGoogle+Email
AHIP CEO steps down
Karen Ignagni will become CEO at New York insurance company EmblemHealth after more than a decade as CEO of America's Health Insurance Plans. Executive Vice President for Strategic Initiatives Dan Durham will serve as interim CEO during the organization's search for a new CEO. The Wall Street Journal (tiered subscription model) (5/21), Politico (5/21)
Share: LinkedInTwitterFacebookGoogle+Email
Calif. insurance exchange caps specialty drug copayments
The Covered California health insurance exchange has announced it will limit specialty drug copayments for most enrollees to $250 per month. An exchange official said premiums across all plans would increase by less than 1% as a result of the change. Bloomberg (5/21)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
J&J: 10 pipeline drugs are potential blockbusters
Johnson & Johnson will submit at least 10 new drugs for review by 2019 and seek more than 40 expanded approvals for existing treatments. Each of the 10 potential new drugs could earn at least $1 billion annually, according to the company, and they include investigational treatments for psoriasis, multiple myeloma and rheumatoid arthritis. Many were developed with partners or licensed from other drugmakers. The Wichita Eagle (Kan.)/The Associated Press (5/20), The Wall Street Journal (tiered subscription model) (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
Editor's Note
SmartBrief will not publish Monday
SmartBrief will not publish Monday in observance of Memorial Day in the U.S. Publication will resume Tuesday.
Share: LinkedInTwitterFacebookGoogle+Email
Rank does not confer privilege or give power. It imposes responsibility."
-- Peter Drucker,
management consultant and writer
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 216 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information